// App-Quantinova.ai

e22026 : Predictive value of circulating tumor cells positive for VEGFR expression in patients with advanced colorectal cancer undergoing treatment with FOLFOX plus bevacizumab.

Researchers

Presenter

  • M. Jose Serrano

Principal Investigators

  • Francisco Gabriel Ortega

  • jose Antonio Lorente

  • Mayte Delgado

  • Jose Luis Puche

Medical Centers

  • Medical Oncology, San Cecilios Hospital, Granada, Spain

  • GENYO, Granada, SpainMedical Oncology, Hospital Universitario Clinico San Cecilio, Granada, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Colorectal Cancer

Biomarkers

  • Circulating tumor cells

  • Kinase Insert Domain Receptor

Drug/Treatment

  • Bevacizumab

  • FOLFOX6

  • Oxaliplatin, 5-fluorouracil and folic acid

Outcome

  • Positive

Study Design

  • observational

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved